Core Viewpoint - As of November 3, 2025, Kangtong Medical (301515) closed at 22.41 yuan, marking a 1.91% increase, with a trading volume of 1.35 million shares and a total transaction value of 30.07 million yuan [1] Financial Performance - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [3] - The net profit attributable to shareholders was -10.21 million yuan, a year-on-year decline of 150.92% [3] - The third quarter of 2025 saw a single-quarter main revenue of 79.12 million yuan, a year-on-year increase of 42.81% [3] - The single-quarter net profit attributable to shareholders was -1.80 million yuan, a year-on-year decrease of 138.94% [3] - The company reported a gross margin of 22.45% [3] Market Position - Kangtong Medical's total market capitalization is 2.24 billion yuan, significantly lower than the industry average of 11.62 billion yuan, ranking 119th in the industry [3] - The company's net assets stand at 1.22 billion yuan, compared to the industry average of 3.89 billion yuan, ranking 99th [3] - The price-to-earnings ratio (P/E) is -164.64, while the industry average is 63.42, ranking 124th [3] - The price-to-book ratio (P/B) is 1.84, compared to the industry average of 4.04, ranking 27th [3] - The company's net profit margin is -3.44%, while the industry average is 9.57%, ranking 102nd [3] Capital Flow - On November 3, 2025, the net inflow of main funds was 2.24 million yuan, accounting for 7.45% of the total transaction value [1][2] - Retail investors experienced a net outflow of 0.11 million yuan, indicating a slight decrease in retail interest [1][2] - Over the past five days, the main funds have fluctuated, with notable net outflows on October 30 and October 29 [2]
股票行情快报：港通医疗（301515）11月3日主力资金净买入223.89万元